Ｐｓｅｕｄｏｍｏｎａｓ　ａｅｒｕｇｉｎｏｓａに対する各種ニューキノロン系抗菌薬のｉｎ　ｖｉｔｒｏおよびｉｎ　ｖｉｖｏにおける抗菌効果の比較検討

DOI 被引用文献1件 参考文献17件

書誌事項

タイトル別名
  • In vitro and in vivo antimicrobial activities of new fluoroquinolones against Pseudomonas aeruginosa.

この論文をさがす

抄録

We investigated the in vitro and in vivo antimicrobial activities of new fluoroquinolones against Pseudomonas aeruginosa.The in vitro antimicrobial activities of ofloxacin (OFLX), ciprofloxacin (CPFX), tosufloxacin (TFLX), sparfloxacin (SPFX), levofloxacin (LVFX), and NM 394, the active form of prodrug NM 441, were examined against 100 clinical isolates of P.aeruginosa.The MIC50s for CPFX, TFLX and NM 394 (0.25μg/ml) were superior to that of LVFX (1.0μg/ml) and OFLX (2.0μg/ml).The in vivo therapeutic efficacies of fluoroquinolones (OFLX, CPFX, LVFX, and NM 441) were evaluated by using a normal and a neutropenic murine model of P.aeruginosa pneumonia.Neutropenia was induced by the single administration of cyclophosphamide at a dose of 200mg/kg of body weight on day 0. Experimental pneumonia was established by intratracheal inoculation of P.aeruginosa on day 3. Antibiotics were administered orally twice a day for 7 days after bacterial challenge.There was no significant difference between the therapeutic effects of CPFX, LVFX, and NM 441 when using normal ddY mice. However, when neutropenic ddY mice were infected with 9×107 CFU of P.aeruginosa, the survival rates of mice were 67%, 33%, and 25% after treatment with NM 441, CPFX, and LVFX, respectively.The difference in survival rates between the NM 441-treated group and the LVFX-treated group was statistically significant (P<0.05).These results suggest that NM 441 has potent antimicrobial activity against P.aeruginosa which shows reduced susceptibility to other fluoroquinolone agents.

収録刊行物

被引用文献 (1)*注記

もっと見る

参考文献 (17)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ